Pages that link to "Q37756120"
Jump to navigation
Jump to search
The following pages link to New developments in the management of cytomegalovirus infection after solid organ transplantation (Q37756120):
Displaying 50 items.
- Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Q24200991) (← links)
- Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation (Q26826856) (← links)
- Infection in Organ Transplantation (Q30238810) (← links)
- Cytomegalovirus: pathogen, paradigm, and puzzle (Q33351523) (← links)
- Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran (Q33624126) (← links)
- Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation (Q33911369) (← links)
- The M33 G protein-coupled receptor encoded by murine cytomegalovirus is dispensable for hematogenous dissemination but is required for growth within the salivary gland (Q34261510) (← links)
- Incidence, risk factors, and outcomes of delayed-onset cytomegalovirus disease in a large, retrospective cohort of heart transplant recipients (Q34729119) (← links)
- Infections in liver transplant recipients. (Q34993661) (← links)
- Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation (Q35694674) (← links)
- Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults (Q35859879) (← links)
- Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients (Q35946563) (← links)
- Delayed-onset cytomegalovirus disease coded during hospital readmission in a multicenter, retrospective cohort of liver transplant recipients. (Q35985337) (← links)
- Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation (Q35990217) (← links)
- IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients (Q36156499) (← links)
- Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole genomic sequencing directly from clinical specimens (Q36331587) (← links)
- Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil (Q36477951) (← links)
- Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus (Q36686842) (← links)
- Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. (Q36694861) (← links)
- Rare presentations of cytomegalovirus infection in renal allograft recipients (Q36734332) (← links)
- Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. (Q36759073) (← links)
- Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir. (Q36950587) (← links)
- Prevention of infection caused by immunosuppressive drugs in gastroenterology. (Q36971789) (← links)
- Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection (Q37254190) (← links)
- Cytomegalovirus infections in solid organ transplantation: a review (Q37359332) (← links)
- Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation (Q37863894) (← links)
- Common Infections in the Lung Transplant Recipient (Q37867765) (← links)
- Antifungal Therapy (Q37916822) (← links)
- Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients (Q37962447) (← links)
- Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients. (Q37998072) (← links)
- Evaluation of elevated liver enzymes (Q38006136) (← links)
- Cytomegalovirus infection and the gastrointestinal tract (Q38010341) (← links)
- Prevention of cytomegalovirus following solid organ transplantation: a literature review (Q38124439) (← links)
- Treatment of cytomegalovirus infections beyond acute disease to improve human health (Q38176940) (← links)
- Diarrhea caused by viruses in transplant recipients (Q38205920) (← links)
- Cytomegalovirus infection in liver transplant recipients: updates on clinical management (Q38242802) (← links)
- The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase (Q38631773) (← links)
- Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals. (Q38941812) (← links)
- Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection (Q39107736) (← links)
- Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent (Q39325580) (← links)
- Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications. (Q40139857) (← links)
- Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants (Q40763966) (← links)
- In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins (Q41233197) (← links)
- Cytomegalovirus reactivation in patients with multiple myeloma (Q41383041) (← links)
- Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis (Q41496012) (← links)
- Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation (Q42202589) (← links)
- Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients. (Q42229846) (← links)
- Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. (Q42259440) (← links)
- Cholecystostomy for acalculous cholecystitis with haemobilia in a lung transplant patient; a case report (Q42752235) (← links)
- Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis (Q42844201) (← links)